MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)*
Organization & Developments: Lexicon
Parents
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)*
Children
*Biopharmaceutical company focused on drug discovery and development.
*Company is dedicated to discovering and developing breakthrough treatments for human disease based on understanding how genes function.
*Has therapies in development for diabetes, IBS, carcinoid syndrome, and rheumatoid arthritis
*Pioneered proprietary gene knockout technology to discover new ways that drugs might work to fight disease and restore health.
2017: Lexicon Pharmaceuticals: Xermelo Off To A Strong Start, Important Pipeline Catalysts Coming Up - Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
2021: Lexicon's Sotagliflozin: New Approach To Safety May Make Approval Easier
2023: Lexicon Pharmaceuticals: Navigating The Competitive HFpEF Landscape (Rating Downgrade)_ seekingalpha.com
2024: FDA rejects Lexicon's Zynquista for diabetes, kidney disease
2024: Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes
2024: Lexicon pens licensing deal with Viatris for sotagliflozin
2024: Lexicon Pharma: Inpefa's Early Clinical Benefits, Rehospitalization Data May Unlock Significant Value_ seekingalpha.com
2024: Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do
2024: Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset
2024: Lexicon to disband sales team, lay off 60% of staff
2024: Lexicon to lay off 50% of field force as it prioritizes heart failure drug, potential US diabetes launch _ fiercepharma
2025: Lexicon Pharmaceuticals faces potential Nasdaq delisting
2025: Lexicon targets late 2025 Phase 3 start for pilavapadin and expands LX9851 partnership with Novo Nordisk
2025: New FDA-Approved Diabetes Drug Slashes Heart Attack and Stroke Risk
2025: Type 2 diabetes drug may lower heart attack, stroke risk by 23%
Jumps
*Key People: Lexicon
Finance & Acquisitions: Lexicon